Ikeuchi Hidekazu, Imai Yoichi, Maruyama Shoichi, Sugiyama Hitoshi, Sato Hiroshi, Yokoyama Hitoshi, Hiromura Keiju
Department of Nephrology and Rheumatology, Gunma Graduate School of Medicine, 3-39-22 Showa, Maebashi, Gunma, 371-8511, Japan.
Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Clin Exp Nephrol. 2025 Jun 4. doi: 10.1007/s10157-025-02709-5.
Membranous lupus nephritis (MLN), a distinct subtype of lupus nephritis (LN), is generally associated with more favorable outcomes than proliferative LN (PLN). However, clinical data regarding pure MLN are limited. We investigated the prognosis of patients with pure MLN in Japan.
We performed a sub-analysis of a previously reported nationwide retrospective cohort study of patients with LN in Japan. This study included patients who underwent renal biopsy between 2007 and 2012. Patients with pure MLN (Class V, n = 90) were compared to those with PLN (Class III/IV ± V, n = 362) over a median follow-up period of 5 years. The primary outcome was defined as a 50% increase in serum creatinine (S-Cr) levels.
The renal and patient outcomes of the pure MLN and PLN groups were as follows: A ≥ 50% increase in S-Cr occurred in 12.2 vs. 16.3% of patients. Doubling of S-Cr or progression to end-stage kidney disease (ESKD) occurred in 4.4 vs. 8.6%, ESKD alone in 2.2 vs. 3.0%, and all-cause mortality in 7.9 vs. 5.5%. After adjusting for age, sex, baseline renal function, proteinuria, and the use of mycophenolate mofetil or intravenous cyclophosphamide, no significant differences in renal outcomes were observed between groups (hazard ratio 0.564; 95% confidence interval 0.272-1.170; P = 0.124).
In this nationwide Japanese cohort, no statistically significant differences in renal outcomes were observed between pure MLN and PLN. Further research is needed to explore strategies to improve outcomes in pure MLN.
膜性狼疮性肾炎(MLN)是狼疮性肾炎(LN)的一种独特亚型,与增殖性LN(PLN)相比,其预后通常更佳。然而,关于纯MLN的临床数据有限。我们调查了日本纯MLN患者的预后情况。
我们对之前报道的一项日本全国性LN患者回顾性队列研究进行了亚分析。该研究纳入了2007年至2012年间接受肾活检的患者。将纯MLN患者(Ⅴ类,n = 90)与PLN患者(Ⅲ/Ⅳ±Ⅴ类,n = 362)进行比较,中位随访期为5年。主要结局定义为血清肌酐(S-Cr)水平升高50%。
纯MLN组和PLN组的肾脏及患者结局如下:S-Cr升高≥50%的患者比例分别为12.2%和16.3%。S-Cr翻倍或进展至终末期肾病(ESKD)的患者比例分别为4.4%和8.6%,仅ESKD的患者比例分别为2.2%和3.0%,全因死亡率分别为7.9%和5.5%。在调整年龄、性别、基线肾功能、蛋白尿以及霉酚酸酯或静脉注射环磷酰胺的使用情况后,两组之间的肾脏结局无显著差异(风险比0.564;95%置信区间0.272 - 1.170;P = 0.124)。
在这个日本全国性队列中,纯MLN和PLN之间在肾脏结局方面未观察到统计学上的显著差异。需要进一步研究以探索改善纯MLN结局的策略。